<?xml version='1.0' encoding='utf-8'?>
<document id="23493821"><sentence text="A review on therapeutic drug monitoring of immunosuppressant drugs." /><sentence text=": Immunosuppressants require therapeutic drug monitoring because of their narrow therapeutic index and significant inter-individual variability in blood concentrations" /><sentence text=" This variability can be because of factors like drug-nutrient interactions, drug-disease interactions, renal-insufficiency, inflammation and infection, gender, age, polymorphism and liver mass" /><sentence text=" Drug monitoring is widely practiced especially for cyclosporine, tacrolimus, sirolimus and mycophenolic acid"><entity charOffset="52-64" id="DDI-PubMed.23493821.s4.e0" text="cyclosporine" /><entity charOffset="66-76" id="DDI-PubMed.23493821.s4.e1" text="tacrolimus" /><entity charOffset="78-87" id="DDI-PubMed.23493821.s4.e2" text="sirolimus" /><entity charOffset="92-109" id="DDI-PubMed.23493821.s4.e3" text="mycophenolic acid" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e0" e2="DDI-PubMed.23493821.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e0" e2="DDI-PubMed.23493821.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e0" e2="DDI-PubMed.23493821.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e0" e2="DDI-PubMed.23493821.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e1" e2="DDI-PubMed.23493821.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e1" e2="DDI-PubMed.23493821.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e1" e2="DDI-PubMed.23493821.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e2" e2="DDI-PubMed.23493821.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23493821.s4.e2" e2="DDI-PubMed.23493821.s4.e3" /></sentence><sentence text=" CYCLOSPORINE: Therapeutic monitoring of immunosuppressive therapy with cyclosporine is a critical requirement because of intra- and inter-patient variability of drug absorption, narrow therapeutic window and drug induced nephrotoxicity"><entity charOffset="1-13" id="DDI-PubMed.23493821.s5.e0" text="CYCLOSPORINE" /><entity charOffset="72-84" id="DDI-PubMed.23493821.s5.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.23493821.s5.e0" e2="DDI-PubMed.23493821.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23493821.s5.e0" e2="DDI-PubMed.23493821.s5.e1" /></sentence><sentence text=" MYCOPHENOLIC ACID MPA: Some reasons for therapeutic drug monitoring of MPA during post-transplant period include: relationship between MPA pharmacokinetic parameters and clinical outcomes, Inter-patient pharmacokinetic variability for MPA despite fixed MMF doses, alternations of MPA pharmacokinetics during the first months after transplantation, drug- drug interaction and influence of kidney function on MPA pharmacokinetic" /><sentence text=" SIROLIMUS: A recent review of the pharmacokinetics of sirolimus suggested a therapeutic range of 5 to 10 Î¼g l(-1) in whole blood"><entity charOffset="1-10" id="DDI-PubMed.23493821.s7.e0" text="SIROLIMUS" /><entity charOffset="55-64" id="DDI-PubMed.23493821.s7.e1" text="sirolimus" /><pair ddi="false" e1="DDI-PubMed.23493821.s7.e0" e2="DDI-PubMed.23493821.s7.e0" /><pair ddi="false" e1="DDI-PubMed.23493821.s7.e0" e2="DDI-PubMed.23493821.s7.e1" /></sentence><sentence text=" However, the only consensus guidelines published on the therapeutic monitoring of sirolimus concluded that there was not enough information available about the clinical use of the drug to make recommendations"><entity charOffset="83-92" id="DDI-PubMed.23493821.s8.e0" text="sirolimus" /></sentence><sentence text=" TACROLIMUS: Sudies have shown, in kidney and liver transplant patients, significant associations of low tacrolimus concentrations with rejection and of high concentrations with nephrotoxicity"><entity charOffset="1-11" id="DDI-PubMed.23493821.s9.e0" text="TACROLIMUS" /><entity charOffset="105-115" id="DDI-PubMed.23493821.s9.e1" text="tacrolimus" /><pair ddi="false" e1="DDI-PubMed.23493821.s9.e0" e2="DDI-PubMed.23493821.s9.e0" /><pair ddi="false" e1="DDI-PubMed.23493821.s9.e0" e2="DDI-PubMed.23493821.s9.e1" /></sentence><sentence text=" Although the feasibility of a limited sampling scheme to predict AUC has been demonstrated, as yet, trough, or pre-dose, whole blood concentration monitoring is still the method of choice" /><sentence text="" /></document>